India's biotech sector needs sustained investment to reach potential

India's biotechnology industry, while expanding rapidly, faces a critical challenge in securing adequate long-term funding mechanisms necessary to support its development trajectory, according to sector experts.

The country has emerged as a significant player in global biotech, leveraging its scientific talent, cost advantages, and regulatory frameworks. However, current investment patterns remain concentrated in short-term ventures, leaving many promising research initiatives and startups without sustained financial backing required for product development and scaling operations.

Experts argue that addressing this capital gap is essential for India to maintain competitive advantage and translate scientific innovation into commercially viable solutions. The biotech sector's growth potential remains substantial, yet realizing it demands institutional investment vehicles and policy frameworks that support multi-year commitments typical of drug discovery, clinical trials, and manufacturing expansion.

Stakeholders across government, industry, and financial institutions are increasingly focusing on how to structure investment mechanisms—including venture capital funds, public-private partnerships, and dedicated biotechnology development banks—that can provide the patient capital necessary for long-term value creation in the sector.